Wouter W. de Herder
YOU?
Author Swipe
View article: Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes
Publisher Correction: Academia Europaea’s guidelines for the visualization of clinical outcomes Open
View article: Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol
Somatostatin analogue continuation upon progression in patients with gastroenteropancreatic neuroendocrine tumour (SAUNA trial): a randomised controlled trial protocol Open
Introduction Gastroenteropancreatic neuroendocrine tumours (GEP NET) are malignant neoplasms that impact survival. Somatostatin analogues (SSA) are used for treating hormonal symptoms caused by GEP NET and have antiproliferative effects. T…
View article: Thomas Hardy and the tallest – blind -man
Thomas Hardy and the tallest – blind -man Open
View article: High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas Open
Introduction Pituitary adenomas/pituitary neuroendocrine tumors (PitNETs) are common intracranial tumors, clinically affecting 1:1000 individuals and most cases remain genetically unexplained. Emerging research has highlighted the major co…
View article: Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome
Serum 5-Hydroxyindoleacetic Acid Measurements for the Diagnosis and Follow-up of Carcinoid Syndrome Open
Context The biochemical diagnosis of carcinoid syndrome (CS) is established through the measurement of 24-hour urine 5-hydroxyindoleacetic acid (5-HIAA), but these measurements are prone to sampling error and may be troublesome for patient…
View article: A new link between insulinoma and congenital glucose-galactose malabsorption
A new link between insulinoma and congenital glucose-galactose malabsorption Open
Congenital glucose-galactose malabsorption (CGGM) is a rare autosomal recessive disorder caused by a biallelic mutation of solute carrier family 5 member 1 ( SLC5A1 ), encoding the sodium-dependent glucose transport-1 (SGLT-1) protein. Pat…
View article: Familial Inactivating Glucagon Receptor Mutation Resulting in Pancreatic Neuroendocrine Tumours with Metastatic Potential, Somatic MEN1 Mutations, and a Heterozygous Phenotype
Familial Inactivating Glucagon Receptor Mutation Resulting in Pancreatic Neuroendocrine Tumours with Metastatic Potential, Somatic MEN1 Mutations, and a Heterozygous Phenotype Open
View article: Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours Open
Peptide receptor radionuclide therapy (PRRT) using [ 177 Lu‐DOTA 0 ,Tyr 3 ]octreotate ( 177 Lu‐DOTATATE) represents an established treatment modality for somatostatin receptor‐positive, locally advanced or metastatic gastroenteropancreatic…
View article: Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovary
Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovary Open
Currently, the available literature provides insufficient support to differentiate between primary ovarian neuroendocrine tumors (PON) and neuroendocrine ovarian metastases (NOM) in patients. For this reason, patients with a well‐different…
View article: Sidonia and Nicu de Barcsy: a famous mother with post-partum hirsutism after giving birth to a famous son with idiopathic short stature
Sidonia and Nicu de Barcsy: a famous mother with post-partum hirsutism after giving birth to a famous son with idiopathic short stature Open
Summary At the end of the 19th century, an 18-year-old lady gave birth to a well-proportioned, though very small, son. After delivery, the mother developed a full-grown beard, whereas the son always remained of small stature. The mother de…
View article: Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients
Ovarian neuroendocrine tumor metastases can induce estrogen production in postmenopausal patients Open
Neuroendocrine tumors (NETs) are malignant neoplasms that can be associated with specific hormonal syndromes. We describe a novel syndrome of postmenopausal vaginal bleeding and ovarian estradiol overproduction due to ovarian NET localizat…
View article: Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET Open
View article: Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN Open
About 500,000 patients with rare adult solid cancers (RASC) are diagnosed yearly in Europe. Delays and unequal quality of management impact negatively their survival. Since 2017, European reference networks (ERN) aim to improve the quality…
View article: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET Open
Background The current standard of care (SoC) for the initial treatment of unresectable or metastatic well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NET) requires initiation of first-generation somatostatin receptor…
View article: Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature
Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature Open
Midgut NET patients have an altered gut microbiome which suggests a role in NET development and could provide novel targets for microbiome-based diagnostics and therapeutics.
View article: What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators
What Is Carcinoid Syndrome? A Critical Appraisal of Its Proposed Mediators Open
Carcinoid syndrome (CS) is a debilitating disease that affects approximately 20% of patients with neuroendocrine neoplasms (NEN). Due to the increasing incidence and improved overall survival of patients with NEN over recent decades, patie…
View article: Approach to the Patient: Insulinoma
Approach to the Patient: Insulinoma Open
Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms with an estimated incidence of 1 to 4 cases per million per year. Extrapancreatic insulinomas are extremely rare. Most insulinomas present with the Whipple triad: (1) sy…
View article: THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making
THU071 Key Device Attributes For Injectable SRL Therapy In Acromegaly And NETs To Aid Clinical Decision Making Open
Disclosure: W.W. de Herder: Research Investigator; Self; Novartis Pharmaceuticals. Speaker; Self; Novartis Pharmaceuticals, Ipsen. S. Melmed: Consulting Fee; Self; Ionis Pharmaceuticals Inc., Ipsen, Novo Nordisk. Grant Recipient; Self; Pfi…
View article: 132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
132MO Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study Open
View article: A bronze statue of the acromegalic giant Rigardus Rijnhout
A bronze statue of the acromegalic giant Rigardus Rijnhout Open
View article: Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion
Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion Open
Introduction Pituitary adenomas (PAs) are common, usually benign tumors of the anterior pituitary gland which, for the most part, have no known genetic cause. PAs are associated with major clinical effects due to hormonal dysregulation and…
View article: One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones
One hundred years after the discovery of insulin and glucagon: the history of tumors and hyperplasias that hypersecrete these hormones Open
One century ago, in 1922, Frederick G Banting, Charles H Best, James B Collip and John J R Macleod first published their experiments resulting in the isolation of a hypoglycemic factor, named insulin, from a solution extract from a dog’s p…
View article: Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms
Effective strategies for adequate control of hormonal secretion in functioning neuroendocrine neoplasms Open
View article: Neuropathic foot ulcers in the tallest patients with acromegalic gigantism: a common and significant problem. Historical overview
Neuropathic foot ulcers in the tallest patients with acromegalic gigantism: a common and significant problem. Historical overview Open
View article: Proposal of early <scp>CT</scp> morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to <scp>RECIST</scp>
Proposal of early <span>CT</span> morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to <span>RECIST</span> Open
RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting…
View article: The Driver Role of Pathologists in Endocrine Oncology: What Clinicians Seek in Pathology Reports
The Driver Role of Pathologists in Endocrine Oncology: What Clinicians Seek in Pathology Reports Open
View article: Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international <scp>HomeLAN</scp> survey
Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international <span>HomeLAN</span> survey Open
Lanreotide autogel/depot (LAN) is a somatostatin analog used in first‐line treatment for neuroendocrine tumors (NETs). The aim of HomeLAN was to evaluate the satisfaction with injection experience among patients with NETs receiving at‐home…
View article: Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors
Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors Open
Background Somatostatin receptor type 2 (SST 2 ) expression is critical for the diagnosis and treatment of neuroendocrine tumors and is associated with improved patient survival. Recent data suggest that epigenetic changes such as DNA meth…
View article: Supplement 2 from Long-Term Efficacy, Survival, and Safety of [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Supplement 2 from Long-Term Efficacy, Survival, and Safety of [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors Open
Supplement Figure 1. Median overall survival for patients receiving a cumulative dose of {greater than or equal to}100 mCi 177Lu-DOTATATE with a primary NET located in the midgut with and without progression at baseline.
View article: Supplement 1 from Long-Term Efficacy, Survival, and Safety of [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Supplement 1 from Long-Term Efficacy, Survival, and Safety of [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors Open
Supplement Table 1. A. Characteristics of the 4 patients with acute leukemia in follow-up